Jafron Biomedical Co

Jafron Biomedical Co Accounts Payable

The Accounts Payable of Jafron Biomedical Co (300529.SZ) as of Nov 12, 2026 is 112.27 M CNY. In the previous year, Accounts Payable was 119.19 M CNY — a change of -5.81% (lower).

Accounts Payable

112.27 MCNY

YoY

-5.81%

Last updated:

Accounts Payable of Jafron Biomedical Co is 2025 112.27 M CNY. Accounts Payable of Jafron Biomedical Co was 2024 119.19 M CNY. It decreases by -5.81% lower compared to the previous year.

The Jafron Biomedical Co Accounts Payable history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Accounts Payable
Date
Accounts Payable
Jan 1, 2018
29.90 M CNY
Jan 1, 2019
32.83 M CNY
Jan 1, 2020
50.22 M CNY
Jan 1, 2021
60.76 M CNY
Jan 1, 2022
128.52 M CNY
Jan 1, 2023
135.62 M CNY
Jan 1, 2024
119.19 M CNY
Jan 1, 2025
112.27 M CNY
The Jafron Biomedical Co Accounts Payable history
YEARAccounts PayableYoY
112.27 MCNY-5.81%
119.19 MCNY-12.12%
135.62 MCNY+5.52%
128.52 MCNY+111.52%
60.76 MCNY+21.00%
50.22 MCNY+52.95%
32.83 MCNY+9.81%
29.90 MCNY+16.58%
25.65 MCNY+28.56%
19.95 MCNY-29.77%
28.41 MCNY+190.22%
9.79 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Jafron Biomedical Co Stock analysis

What does Jafron Biomedical Co do? Jafron Biomedical Co., Ltd. generates revenue through the research, development, production, and sale of hemoperfusion products and medical equipment. The company offers a range of items including disposable hemoperfusion devices, hemoperfusion machines, disposable bilirubin adsorbers, the DX-10 blood purification machine, suture needles, and resins bandage. These products are utilized for treating conditions such as uremia, poisoning, severe liver diseases, autoimmune diseases, and multisystem organ failure. The primary customers for these medical solutions are hospitals across China, where the company’s products are applied in more than 3000 hospitals within 31 provinces. As a China-based company, Jafron Biomedical Co., Ltd. focuses on the design, manufacture, and distribution of biological materials and medical equipment to support healthcare providers in these regions. The company operates from its headquarters in Zhuhai, Guangdong, and supports its operations with a workforce of 3,003 full-time employees. By engaging in the full lifecycle of its products from research to sale, the firm serves the medical sector with specialized equipment for blood purification and related therapeutic needs. Jafron Biomedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Jafron Biomedical Co stock

Accounts Payable of Jafron Biomedical Co is 112.27 M CNY in 2025.

Accounts Payable of Jafron Biomedical Co changed from 119.19 M CNY to 112.27 M CNY, representing a -5.81% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Accounts Payable Jafron Biomedical Co since 2006 – with annual values, charts, and detailed analysis.

Accounts payable represents money owed to suppliers for goods and services received. It is a key component of working capital management.

Accounts Payable's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Payable's Jafron Biomedical Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Jafron Biomedical Co

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Jafron Biomedical Co